Concepts (85)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dasatinib | 6 | 2018 | 50 | 0.560 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 4 | 2018 | 11 | 0.520 |
Why?
|
| Antibodies, Bispecific | 2 | 2025 | 52 | 0.430 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2025 | 153 | 0.400 |
Why?
|
| Imatinib Mesylate | 6 | 2018 | 48 | 0.380 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2018 | 605 | 0.370 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2016 | 103 | 0.350 |
Why?
|
| Antineoplastic Agents | 5 | 2016 | 1825 | 0.240 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2018 | 268 | 0.220 |
Why?
|
| Thiazoles | 2 | 2014 | 100 | 0.200 |
Why?
|
| Sentinel Lymph Node | 1 | 2023 | 11 | 0.200 |
Why?
|
| Febrile Neutropenia | 1 | 2022 | 15 | 0.200 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 767 | 0.180 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2022 | 130 | 0.180 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 233 | 0.170 |
Why?
|
| Pyrimidines | 2 | 2014 | 418 | 0.170 |
Why?
|
| Disease-Free Survival | 6 | 2018 | 958 | 0.160 |
Why?
|
| Chymases | 1 | 2018 | 3 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2025 | 1304 | 0.140 |
Why?
|
| Drug Substitution | 1 | 2018 | 21 | 0.140 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2025 | 898 | 0.140 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 573 | 0.130 |
Why?
|
| Benzamides | 2 | 2014 | 124 | 0.130 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 1 | 2016 | 1 | 0.130 |
Why?
|
| Lymphocytosis | 1 | 2016 | 14 | 0.120 |
Why?
|
| Melanoma | 1 | 2023 | 950 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 897 | 0.120 |
Why?
|
| Piperazines | 2 | 2014 | 256 | 0.110 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 7097 | 0.110 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 385 | 0.100 |
Why?
|
| Aged | 8 | 2025 | 21385 | 0.090 |
Why?
|
| Middle Aged | 9 | 2025 | 28943 | 0.090 |
Why?
|
| Treatment Outcome | 7 | 2025 | 12991 | 0.080 |
Why?
|
| Adult | 8 | 2025 | 31536 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 1127 | 0.070 |
Why?
|
| Young Adult | 5 | 2025 | 9952 | 0.070 |
Why?
|
| Male | 10 | 2025 | 64870 | 0.070 |
Why?
|
| Papillomaviridae | 2 | 2018 | 183 | 0.060 |
Why?
|
| Female | 10 | 2025 | 70584 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2016 | 83 | 0.060 |
Why?
|
| Pleural Effusion | 2 | 2016 | 110 | 0.060 |
Why?
|
| Humans | 12 | 2025 | 131924 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2023 | 76 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 1293 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2023 | 72 | 0.050 |
Why?
|
| Indocyanine Green | 1 | 2023 | 63 | 0.050 |
Why?
|
| Azacitidine | 1 | 2022 | 53 | 0.050 |
Why?
|
| Optical Imaging | 1 | 2023 | 72 | 0.050 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2022 | 76 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 5408 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2023 | 5163 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2016 | 808 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2023 | 17374 | 0.040 |
Why?
|
| Treponema denticola | 1 | 2018 | 2 | 0.040 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2018 | 8 | 0.040 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2018 | 10 | 0.040 |
Why?
|
| Disease Progression | 1 | 2025 | 2221 | 0.040 |
Why?
|
| Finland | 1 | 2017 | 46 | 0.030 |
Why?
|
| Neck Dissection | 1 | 2017 | 31 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2017 | 104 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 167 | 0.030 |
Why?
|
| Prognosis | 2 | 2018 | 5007 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 124 | 0.030 |
Why?
|
| Pancytopenia | 1 | 2016 | 40 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 435 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2016 | 88 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 213 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1342 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 663 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 1693 | 0.030 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 43 | 0.030 |
Why?
|
| Time | 1 | 2014 | 98 | 0.030 |
Why?
|
| Cytogenetic Analysis | 1 | 2013 | 81 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2016 | 348 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1572 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 519 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 1361 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 439 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 1246 | 0.020 |
Why?
|
| Adolescent | 2 | 2023 | 20535 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 2056 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 3375 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 3732 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 6440 | 0.010 |
Why?
|
| Child | 1 | 2023 | 25761 | 0.010 |
Why?
|